On April 8, 2022 BroadenBio Co., Ltd. (BroadenBio) reported the completion of PreA+ round of financing of tens of millions (CNY) (Press release, BroadenBio, APR 8, 2022, View Source [SID1234640198]). The financing was led by the original shareholder Tao Capital, followed by Minkang Health Technology, and the original shareholder Lapam Capital continued to increase investment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The funding will primarily be used for the Phase 1 clinical trial of the potentially Best-in-Class (BIC) investigational drug BB102. In addition, the investment will also be used in the development of international cutting-edge small molecule inhibitors of intracellular immune checkpoint, and the preclinical study of globally First-in-Class (FIC) small molecule drug candidates that play immune activation and tumor suppression dual functions, as well as establishing a top-level immunology and small molecule coupling technology platform.
"We are very grateful to all investors, to Lapam Capital and Tao Capital, the well-known investment institutions in the industry, for their long-term support and companionship," said Xingmin Zhang, M.D., Ph.D., founder and Chief Executive Officer of BroadenBio. "BroadenBio has always been adhering to the original intention of its establishment, Gathering Talents, For Innovation, applying our unique technology platforms in the discovery and development of FIC and BIC innovative drugs, benefiting human health with immune technology."
Since its foundation, the company’s R&D pipeline has covered various fields such as oncology, autoimmune disease, and infection. Characteristic technology platforms are becoming increasingly perfect, and the R&D center has begun to take shape.